OYE Therapeutics Administers First Patient Dose in Pioneering 505(b)(2) Bridging Study
In a groundbreaking advancement poised to reshape perioperative and emergency medicine, OYE Therapeutics Inc., a clinical-stage biotechnology firm, has announced ...
